FDA calls public meeting to explore scope of dietary supplement ingredients under DSHEA

Published: 9-Mar-2026
Regulatory

The FDA has announced a public meeting on 27 March to gather stakeholder feedback on the definition of dietary ingredient categories, including proteins, enzymes and microbials, as it considers its next regulatory steps

The US Food and Drug Administration is holding a public meeting to gather feedback on dietary ingredient categories, including proteins, enzymes and microbes.

The meeting, scheduled for March 27, 2026, is titled "Exploring the Scope of Dietary Supplement Ingredients."

The FDA said it will help inform the agency of its next steps "regarding the meaning of the dietary ingredient categories defined in the Dietary Supplement Health and Education Act (DSHEA) of 1994."

During this event, there will be presentations to provide background on the following topics:

  • The scope of the phrase "dietary substance for use by man to supplement the diet by increasing the total dietary intake" as used in DSHEA
  • New methodologies to produce existing dietary ingredients
  • Specific ingredient types, including proteins, enzymes and microbials.

Participants in the meeting will be able to give feedback during the session and submit comments for the agency's review.

Registration details and comment submission instructions will be available on the FDA's meeting page.

  • Companies:
  • US Food and Drug Administration (FDA)
See more

You may also like

Regulatory

FDA to reassess the safety of food preservative BHA

Read more
The review will assess whether BHA is safe under its current conditions of use in foods such as meats, crisps and other processed products

Trending Articles

  1. dsm-firmenich strengthens HMO offering in Asia with new regulatory approvals The company continues its regulatory success in Asia’s early life nutrition market with approval of four new HMOs in Malaysia and Thailand, alongside commercial authorisation of its 3’-SL ingredient in China
  2. K. Patel Phyto Extractions marks 21 years with corporate film Company showcases vertically integrated botanical manufacturing, traceability and sustainable operations
  3. Study finds Metabolaid helps support weight management Ingredient by Monteloeder was able to reduce body weight and fat mass regardless of physical activity or diet
  4. Niagen Bioscience secures US patent for NR IV and injectable formulations The company has been granted a US Patent covering intravenous and injectable formulations of nicotinamide riboside (Niagen), strengthening its position in the fast-growing NAD+-boosting clinic market
  5. Australia sets the global standard for NMN in therapeutic goods Australia has become the first country globally to formally regulate trending longevity ingredient nicotinamide mononucleotide (NMN) for therapeutic goods, marking a major milestone for the expanding global NMN market

Upcoming event

Making Nutraceuticals

21–22 April 2026 | Conference/Exhibition | Coventry, UK See all

You may also like

Regulatory

FDA to reassess the safety of food preservative BHA

The review will assess whether BHA is safe under its current conditions of use in foods such as meats, crisps and other processed products
Regulatory

FDA eases “no artificial colours” claims and expands natural food dye options

The FDA has announced a new enforcement approach allowing “no artificial colours” claims for products free from petroleum-based dyes, alongside approving beetroot red and expanded spirulina extract use to support a shift toward naturally derived food colourings
Regulatory

Florida study finds arsenic in children's sweets

The results from the investigation generate questions for the industry about how food safety data is gathered, assessed, framed and politicised
Regulatory

FDA investigates Live it Up's Super Greens powder for Salmonella outbreak

The brand has initiated a voluntary recall of the greens powder as the regulatory body warns: do not eat, sell or serve certain Live it Up-brand Super Greens dietary supplement powder
Regulatory

FDA faces legal challenge from Alliance for Natural Health over blocked nutrient health claims

The Alliance for Natural Health (ANH-USA) is set to sue the US FDA after the agency rejected a petition seeking approval for 118 nutrient-disease claims, citing violations of the First Amendment and federal law
Regulatory

FDA signals possible easing of dietary supplement disclaimer requirements

The US FDA is considering a regulatory change that could reduce how often the DSHEA disclaimer appears on dietary supplement labels, with the aim to cut costs and label clutter
Regulatory

FDA reverses stance to confirm NMN is lawful for use in dietary supplements

The agency’s decision marks a major policy shift, overturning its previous exclusion of NMN and clarifying the ingredient’s place in the supplement market
Subscribe now